<DOC>
	<DOCNO>NCT01299805</DOCNO>
	<brief_summary>The purpose study evaluate pharmacodynamics ( drug 's effect body ) , pharmacokinetics ( body 's handling drug ) , safety tolerability vortioxetine , daily ( QD ) healthy men .</brief_summary>
	<brief_title>Effects Vortioxetine ( Lu AA21004 ) Concentrations Selected Neurotransmitters Healthy Male Adults</brief_title>
	<detailed_description>This study look investigational medicine call vortioxetine see drug affect body body handle drug . The study enrol 17 patient . Participants randomly assign 2:1 ratio one follow two treatment groups—which remain undisclosed participant study doctor study ( unless urgent medical need ) : - Vortioxetine 20 mg - Placebo ( dummy inactive pill ) - capsule look like study drug active ingredient . All participant ask take one capsule time day throughout study . This single-center trial conduct United States . The overall time participate study approximately 7 week . Participants make 2 visit clinic , include 18 day confinement clinic , contact telephone 1 day 27 day leave confinement follow-up assessment .</detailed_description>
	<mesh_term>Vortioxetine</mesh_term>
	<mesh_term>Neurotransmitter Agents</mesh_term>
	<criteria>Weighs least 50 kg body mass index 19.0 32.0 kg/m^2 , inclusive Screening . Males nonsterilized sexually active female partner childbearing potential must agree use adequate contraception signing inform consent throughout duration study 6 week last dose study medication . The acceptable method contraception define one high 1 % failure rate . Received investigational compound within 45 day prior Checkin ( Day 2 ) . Received Lu AA21004 previous clinical study therapeutic agent . History uncontrolled , clinically significant neurologic , cardiovascular , pulmonary , central nervous system , hepatic hematopoietic disease , renal metabolic , gastrointestinal , endocrine disease , serious allergy , asthma , hypoxemia , hypertension , seizure , allergic skin rash abnormality , may impact ability participant participate potentially confound study result . Participant 1 follow : Any current psychiatric disorder define Diagnostic Statistical Manual Mental Disorders , Fourth Edition Text Revision ( DSMIVTR ) . Current history : manic hypomanic episode , schizophrenia psychotic disorder , include major depression psychotic feature , mental retardation , organic mental disorder , mental disorder due general medical condition define DSMIVTR . Presence history clinically significant neurological disorder ( include epilepsy ) . Neurodegenerative disorder ( Alzheimer disease , Parkinson disease , multiple sclerosis , Huntington disease , etc ) . Any Axis II disorder . Has know hypersensitivity component formulation Lu AA21004 . Has positive urine drug result drug abuse Screening Checkin ( Day 2 ) . Has history drug abuse ( define illicit drug use ) history alcohol abuse ( define regular consumption 4 unit per day ) within 1 year prior Screening visit unwilling agree abstain alcohol drug throughout study . One unit equivalent halfpint beer 1 measure spirit 1 glass wine . The participant intend impregnate donate sperm course study 6 week last dose . Has current recent ( within 6 month ) gastrointestinal disease would expect influence absorption drug ( e.g. , history malabsorption , esophageal reflux , peptic ulcer disease , erosive esophagitis ; frequent ( per week ) occurrence heartburn , intraabdominal surgery ( except laparoscopic cholecystectomy uncomplicated appendectomy ) . Has history cancer , basal cell Stage 1 squamous cell carcinoma skin remission least 5 year prior Day 1 . Has positive test result hepatitis B surface antigen ( HBsAg ) , hepatitis C antibody Screening know history human immunodeficiency virus infection . Has use nicotinecontaining product ( include limit cigarette , pipe , cigar , chew tobacco , nicotine patch nicotine gum ) within 28 day prior Checkin ( Day 2 ) unwilling abstain product duration study . Cotinine test positive Screening Checkin ( Day 2 ) . Has poor peripheral venous access . Has donate lose 450 mL blood volume ( include plasmapheresis ) , transfusion blood product within 30 day prior Day 1 . Has Screening Checkin ( Day 2 ) abnormal ( clinically significant ) electrocardiogram ( ECG ) . Entry patient abnormal ( clinically significant ) ECG must approve , document signature principal investigator . Has abnormal Screening Day 2 laboratory value suggest clinically significant underlying disease follow lab abnormality : alanine aminotransferase and/or aspartate aminotransferase &gt; 1.5 time upper limit normal . Has cerebrospinal fluid ( CSF ) collection perform within 30 day prior Checkin ( Day 2 ) . Has take selective serotonin reuptake inhibitor ( SSRIs ) , selective norepinephrine reuptake inhibitor ( SNRIs ) , monoamine oxidase inhibitor , antipsychotic , tricyclic antidepressant , mood stabilizer within last year prior Screening . Has know hypersensitivity anesthetic derivative use CSF collection , medication use prepare area lumbar puncture . Has significant vertebral deformity ( scoliosis kyphosis ) , opinion investigator , may interfere lumbar puncture procedure . Has history clinically significant back pain and/or injury . Has local infection puncture site . Has history significant bleeding coagulation disorder and/or low platelet level ( &lt; 130x10^9/L ) increase international normalized ratio ( INR ) ( &gt; 1.3 ) Screening . Answers positive suicidal ideation and/or suicidal behavior question administration ColumbiaSuicide Severity Rating Scale . Has orthostatic blood pressure drop ≥20 mm Hg ( base drop supine stand [ 3 minute ] systolic blood pressure ) Screening Checkin ( Day 2 ) . Has abnormal Screening Day 2 vital sign : rest systolic blood pressure ≤90 ≥140 mm Hg rest diastolic blood pressure ≤50 ≥90 mm Hg supine position ; rest pulse heart rate ( read ECG ) &lt; 45 bpm &gt; 100 bpm . No 2 repeat measurement . Exercises extensively normal life ( e.g. , marathon running , triathlon , physical sport contest level etc ) .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>Drug Therapy</keyword>
	<keyword>pharmacodynamic</keyword>
</DOC>